CRISPR-HAWK: Haplotype- and Variant-Aware Guide Design Toolkit for CRISPR-Cas
MOTIVATION: Current CRISPR guide RNA design tools rely on reference genomes, overlooking how genetic variation impacts editing outcomes. As genome editing advances toward clinical applications, incorporating population diversity becomes essential for ensuring therapeutic efficacy across diverse populations. RESULTS: We present CRISPR-HAWK, a framework integrating individual- and population-scale variants and haplotypes into gRNA design. Analyzing therapeutic targets across 79,648 genomes reveals that genetic variants substantially alter guide performance. For the clinically approved sickle cell disease therapeutic guide targeting BCL11A, we identify haplotypes that completely abolish predicted cutting activity. Across seven therapeutic loci, 82.5% of guides contain variants modifying on-target activity. Variants also create novel protospacer adjacent motif sites generating individual-specific guides invisible to reference-based design. These findings demonstrate that variant-aware selection is critical for equitable genome editing. AVAILABILITY: CRISPR-HAWK is available at https://github.com/pinellolab/CRISPR-HAWK and https://github.com/InfOmics/CRISPR-HAWK. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Authors
- Rosalba Giugno (ORCID: https://orcid.org/0000-0001-9843-7638)
- Manuel Tognon (ORCID: https://orcid.org/0000-0002-6707-2071)
- Luca Pinello (ORCID: https://orcid.org/0000-0003-1109-3823)
- Nicola Bombieri (ORCID: https://orcid.org/0000-0003-3256-5885)
- Alisa Kumbara (ORCID: https://orcid.org/0009-0002-3899-3928)
- Arianna Fontanesi (ORCID: https://orcid.org/0009-0003-1422-5323)
- Giulia Carone (ORCID: https://orcid.org/0009-0001-4717-9859)
Institutions
- Broad Institute (US)
- University of Verona (IT)
- Harvard University (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Bioinformatics
- Published
- 2026-10-14
- DOI
- https://doi.org/10.1093/bioinformatics/btag708
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Massachusetts General Hospital
- Università degli Studi di Verona
- National Institutes of Health